Current Problems in Cancer: Case Reports (Jun 2022)
EGFR-mutated, metastatic pulmonary pleomorphic carcinoma successfully treated with afatinib
- Akira Kawamura,
- Yuko Tanaka,
- Yusuke Inoue,
- Takashi Tsuchida,
- Mineo Katsumata,
- Masato Karayama,
- Hironao Hozumi,
- Yuzo Suzuki,
- Kazuki Furuhashi,
- Noriyuki Enomoto,
- Tomoyuki Fujisawa,
- Yutaro Nakamura,
- Naoki Inui,
- Takafumi Suda
Affiliations
- Akira Kawamura
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
- Yuko Tanaka
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Corresponding author.
- Yusuke Inoue
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan.
- Takashi Tsuchida
- Department of Diagnostic Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
- Mineo Katsumata
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
- Masato Karayama
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Clinical Oncology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
- Hironao Hozumi
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
- Yuzo Suzuki
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
- Kazuki Furuhashi
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
- Noriyuki Enomoto
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
- Tomoyuki Fujisawa
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
- Yutaro Nakamura
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
- Naoki Inui
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan.
- Takafumi Suda
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
- Journal volume & issue
-
Vol. 6
p. 100160
Abstract
Pulmonary pleomorphic carcinoma (PPC) has an aggressive clinical course and poor prognosis mainly because of the difficulty in achieving therapeutic effects. Despite a small fraction of patients with PPC possessing an epidermal growth factor receptor (EGFR) activating mutation, only a limited number of studies have reported the efficacy of EGFR tyrosine kinase inhibitors in those patients. Here, we present successful treatment with first-line afatinib in a patient with EGFR mutation-positive, metastatic PPC.
